Antibe Therapeutics Inc.
ATE
शेयरों में रैंक
#31892
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
शेयर मूल्य
$0.21483059
अंतिम समन्वयन: 2024-05-07
मार्केट कैप
$11.13M
बदलाव (1 दिन)
0.34%
बदलाव (1 वर्ष)
-0.36%
देश
CA
व्यापार Antibe Therapeutics Inc. (ATE)
श्रेणी
Healthcare
Antibe Therapeutics Inc. (ATE) के लिए डिविडेंड यील्ड इतिहास
Antibe Therapeutics Inc. (स्टॉक सिंबल: ATE) की डिविडेंड यील्ड (TTM) 2026 को: 0
पिछले 5 वर्षों की औसत डिविडेंड यील्ड: 0.00%
पिछले 5 वर्षों की औसत डिविडेंड यील्ड: 0.00%
Antibe Therapeutics Inc. (ATE) के लिए 2026 से 2026 तक की डिविडेंड यील्ड का इतिहास
प्रत्येक वर्ष के अंत में डिविडेंड यील्ड (TTM)
| वर्ष | डिविडेंड यील्ड | परिवर्तन |
|---|---|---|
| प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं। | ||
समान कंपनियों या प्रतिस्पर्धियों के लिए डिविडेंड यील्ड (TTM)
| कंपनी | डिविडेंड यील्ड | देश |
|---|---|---|
| 2.45% |
US
|
|
| 3.69% |
IE
|
|
| 1.25% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
DE
|
